[Personal experience with replacement therapy with intravenous gamma globulin].
Replacement therapy with intravenous immunoglobulin (IVIG) is currently the therapy of choice in patients with antibody-formation deficiency. Our 30-month experience with IVIG treatment in 8 patients with common variable immunodeficiency and in 4 patients with x-linked agammaglobulinemia previously treated by intramuscular immunoglobulin or low-dose IVIG is presented. Long-term dosage was 400 mg/kg once in 3--4 weeks. Ten patients reported an improvement of their health state, especially the signs of their chronic bronchitis improved. Compared to 2 cases of pneumonia which occurred within 30 months before IVIG therapy had started, no case of pneumonia occurred during IVIG treatment. Infusion rate of 4 mg/kg/min was safe enough in 11 of our patients. Serum trough IgG level is the most important for laboratory monitoring of the patients under IVIG therapy.
Litzman
J
J
Ustav klinické imunologie LF Masarykovy univerzity, FN u sv. Anny, Brno.
Lokaj
J
J
Stikarovská
D
D
Mayer
J
J
Thon
V
V
Eibl
M M
MM
D000328:Adult; D000361:Agammaglobulinemia / Q000276:immunology / Q000628:therapy*; D017074:Common Variable Immunodeficiency / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D016756:Immunoglobulins, Intravenous
Nase zkusenosti se substitucní lécbou intravenózním gamaglobulinem.